Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
about
Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?Old and New Biological Therapies for Psoriasis.Pathogenesis of psoriasis and development of treatment.Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.Autoimmunity and autoimmune co-morbidities in psoriasis.Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.
P2860
Q38632525-01E10592-070C-4A19-B936-7DD859F58249Q38707920-69A66FD1-379F-4DA1-A8A3-6C5F7CFB3AD4Q38990571-39A32143-E3D8-4C47-84CE-60966A900FAEQ40164166-57FC5A10-3419-4495-A67B-BA4FBB8D4179Q46247849-2BC66C09-4424-4964-AEEA-11AA8DDA10A9Q47859049-6A79EFD9-9AAF-4BF1-A2A5-D05142D7771EQ48144635-5C32333A-46A0-449C-91F9-D25680CFD805Q48170767-6F9FF5C8-5DE7-4C75-8895-F49F62508514Q48283379-5015FAFD-3931-47F4-8ED4-FF7713C91179Q53835593-D649DA67-3FAD-4C8F-9943-DC95DEB934BFQ55101112-E19CA128-F545-460D-8CF0-276B74AD808C
P2860
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Efficacy and safety of ixekizu ...... bel, phase 3 study (UNCOVER-J)
@ast
Efficacy and safety of ixekizu ...... bel, phase 3 study (UNCOVER-J)
@en
type
label
Efficacy and safety of ixekizu ...... bel, phase 3 study (UNCOVER-J)
@ast
Efficacy and safety of ixekizu ...... bel, phase 3 study (UNCOVER-J)
@en
prefLabel
Efficacy and safety of ixekizu ...... bel, phase 3 study (UNCOVER-J)
@ast
Efficacy and safety of ixekizu ...... bel, phase 3 study (UNCOVER-J)
@en
P2093
P2860
P356
P1476
Efficacy and safety of ixekizu ...... bel, phase 3 study (UNCOVER-J)
@en
P2093
Gregory S Cameron
Hidehisa Saeki
Hidemi Nakagawa
Japanese Ixekizumab Study Group
Olawale O Osuntokun
Taeko Ishii
Takehiro Aoki
Yoji Morisaki
P2860
P304
P356
10.1111/1346-8138.13622
P577
2016-10-11T00:00:00Z